销售持续增长，两大双抗顺利纳入医保。康方生物2024 年总营收为21.2亿元（-53%），下降主要由于授权费用的减少；扣除分销成本后销售收入为20.0 亿元（+25%），增长主要由卡度尼利和依沃西的销售驱动。全年研发费用为11.9 亿元（-5%），销售费用为10.0 亿元（+13%），全年亏损约5.0 亿元。截至24 年底，公司在手现金约73 亿元（上年同期约49 亿元），足以为公司的研发投入及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.